carlsbad, california, September 8, 2022 /PRNewswire/ — Emerge Diagnostics Inc. has received an international patent using EFA: Method for Determining if Determining if Surgically-Implanted Hardware should be Removed.
This patent adds to Emerge’s deep intellectual property portfolio and focuses on using EFA technology at a hardware-implemented site to determine if surgical removal is necessary. The patent was co-authored by Emerge Diagnostics co-founder and his CTO Phil Reaston and MaryRose Cusimano-Reaston, PhD. CSO, COO, Co-Founder Emerged Diagnostics, Frank TomesekMD, Associate Medical Director, Emerge Diagnostics.
The company’s technology allows surgeons to more objectively determine whether spinal hardware needs to be removed, reducing the number of second surgeries and improving patient outcomes. “This is an important milestone for Emerge Diagnostics. We are committed to providing our patients with the best possible care, and this technology helps us achieve just that.”
This patent describes a method of treating patients with surgically implanted hardware by providing objective information that helps surgeons determine whether the implant is still needed or can be safely removed. This technology has the potential to change the standard of care for these patients and reflects our commitment to better outcomes for everyone.
Today’s announcement celebrates Emerge’s portfolio of wellness solutions that provide 360-degree care for employees and their families. The Emerge Wellness solution includes the first patent of its kind for preventative care for employees and their families and determining if surgically implanted hardware should be removed. .
Musculoskeletal conditions are a major medical expense for employees, their families, health insurance and employers. The system over-prescribes pain medications and elective surgery, while failing to provide preventive care and non-surgical solutions. Reducing waste and improving results is important to everyone.
About Emerge Diagnostics
Emerge Diagnostics is a medical solutions company committed to keeping workers and their families safe, both on and off the job, by preventing injuries and coordinating recovery.
The company’s Electrodiagnostic Functional Assessment (EFA) technology is the gold standard for diagnosing and treating soft tissue injuries, using a number of proprietary techniques to assess root cause and can be assessed from virtually anywhere in the world. Emerge Diagnostics serves clients in multiple industries, including trucking, healthcare, and sports, to more accurately treat soft tissue injuries and build objective, data-driven care management and monitoring programs. provide the necessary information for www.emergedx.com.
If you have any questions or need more information, please contact us at: [email protected].
SOURCE Emergency diagnosis
.
Comments
Post a Comment